Select your country

21.11.2016
STADA acquires UK branded product company Natures Aid
STADA acquires UK branded product company Natures Aid

STADA acquires UK branded product company Natures Aid

Read more

14.11.2016
STADA receives “positive opinion” from the EMA for teriparatide biosimilar
STADA receives “positive opinion” from the EMA for teriparatide biosimilar

STADA receives “positive opinion” from the EMA for teriparatide biosimilar

Read more

10.11.2016
STADA records further growth in the first nine months of 2016 – Adjusted net income of at least Euro 180 million now expected for full year 2016
STADA records further growth in the first nine months of 2016 – Adjusted net income of at least Euro 180 million now expected for full year 2016

STADA records further growth in the first nine months of 2016 – Adjusted net income of at least Euro 180 million now expected for full year …

Read more

05.10.2016
STADA lays the groundwork for sustainable growth
STADA lays the groundwork for sustainable growth

STADA lays the groundwork for sustainable growth

Read more

29.09.2016
STADA: Sebastian Krämer-Bach to take on responsibility for expanded Corporate Communications
STADA: Sebastian Krämer-Bach to take on responsibility for expanded Corporate Communications

STADA: Sebastian Krämer-Bach to take on responsibility for expanded Corporate Communications

Read more

05.09.2016
Leslie Iltgen is the new Vice President Investor Relations
Leslie Iltgen is the new Vice President Investor Relations

STADA: Leslie Iltgen is the new Vice President Investor Relations

Read more

27.08.2016
STADA Annual General Meeting 2016
STADA Annual General Meeting 2016

STADA Annual General Meeting: Executive Board presents updated strategy, confirms outlook for financial year 2016 – five new members elected…

Read more

27.08.2016
STADA: Supervisory Board elects Carl Ferdinand Oetker as new Chairman of the Board
STADA: Supervisory Board elects Carl Ferdinand Oetker as new Chairman of the Board

STADA: Supervisory Board elects Carl Ferdinand Oetker as new Chairman of the Board

Read more

26.08.2016
STADA: Shareholder Meeting resolves to remove supervisory board chairman Dr. Martin Abend from the supervisory board
STADA: Shareholder Meeting resolves to remove supervisory board chairman Dr. Martin Abend from the supervisory board

STADA: Shareholder Meeting resolves to remove supervisory board chairman Dr. Martin Abend from the supervisory board

Read more

15.08.2016
Hartmut Retzlaff resigns from office
Hartmut Retzlaff resigns from office

Hartmut Retzlaff resigns from office

Read more

04.08.2016
STADA: Excellent business development in the first six months of 2016
STADA: Excellent business development in the first six months of 2016

STADA: Excellent business development in the first six months of 2016 – reported and adjusted key earnings figures significantly above previ…

Read more

21.07.2016
STADA: Statement on media reports
STADA: Statement on media reports

STADA: Statement on media reports

Read more

20.07.2016
STADA announces agenda for the Annual General Meeting 2016
STADA announces agenda for the Annual General Meeting 2016

STADA announces agenda for the Annual General Meeting 2016

Read more

11.07.2016
STADA approves growth targets for 2019
STADA approves growth targets for 2019

STADA approves growth targets for 2019: adjusted Group sales Euro 2.6 billion, adjusted EBITDA Euro 510 million and adjusted net income Euro…

Read more

06.07.2016
Important step on the path to reconfiguring the STADA Supervisory Board
Important step on the path to reconfiguring the STADA Supervisory Board

Important step on the path to reconfiguring the STADA Supervisory Board

Read more

05.06.2016
Change in leadership at STADA
Change in leadership at STADA

Change in leadership at STADA

Read more

05.06.2016
Change in Chief Executive Officer at STADA Arzneimittel AG
Change in Chief Executive Officer at STADA Arzneimittel AG

Change in Chief Executive Officer at STADA Arzneimittel AG

Read more

22.05.2016
STADA begins process for significant renewal of its Supervisory Board
STADA begins process for significant renewal of its Supervisory Board

STADA begins process for significant renewal of its Supervisory Board

Read more

22.05.2016
STADA: Significant renewal of Supervisory Board brought forward by two years – Annual General Meeting 2016 postponed to August 26, 2016
STADA: Significant renewal of Supervisory Board brought forward by two years – Annual General Meeting 2016 postponed to August 26, 2016

STADA: Significant renewal of Supervisory Board brought forward by two years – Annual General Meeting 2016 postponed to August 26, 2016

Read more

13.05.2016
STADA: STADA allows elaborated motion from Active Ownership Fund as supplement to the Annual General Meeting 2016
STADA: STADA allows elaborated motion from Active Ownership Fund as supplement to the Annual General Meeting 2016

STADA: STADA allows elaborated motion from Active Ownership Fund as supplement to the Annual General Meeting 2016

Read more

12.05.2016
STADA: First quarter of 2016 better than expected – reported key earnings figures substantially higher than previous year – very strong development of the German Generics segment
STADA: First quarter of 2016 better than expected – reported key earnings figures substantially higher than previous year – very strong development of the German Generics segment

STADA: First quarter of 2016 better than expected – reported key earnings figures substantially higher than previous year – very strong deve…

Read more

26.04.2016
STADA: Successful refinancing through the securing of additional promissory note loans of a total of Euro 350 million
STADA: Successful refinancing through the securing of additional promissory note loans of a total of Euro 350 million

STADA: Successful refinancing through the securing of additional promissory note loans of a total of Euro 350 million

Read more

23.03.2016
STADA: Development in 2015 as expected under difficult framework conditions – dividend to increase – outlook for 2016 confirmed
STADA: Development in 2015 as expected under difficult framework conditions – dividend to increase – outlook for 2016 confirmed

STADA: Development in 2015 as expected under difficult framework conditions – dividend to increase – outlook for 2016 confirmed

Read more

29.02.2016
STADA: Development as expected in 2015 under difficult framework conditions – dividend to increase – preliminary outlook for 2016 published
STADA: Development as expected in 2015 under difficult framework conditions – dividend to increase – preliminary outlook for 2016 published

STADA: Development as expected in 2015 under difficult framework conditions – dividend to increase – preliminary outlook for 2016 published

Read more

11.01.2016
STADA: Appointment of Dr. Matthias Wiedenfels extended
STADA: Appointment of Dr. Matthias Wiedenfels extended

STADA: Appointment of Dr. Matthias Wiedenfels extended

Read more